Navigation Links
Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference
Date:9/8/2010

NEW YORK, Sept. 8 /PRNewswire/ -- Regenicin™ (OTC Bulletin Board: WDST), a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, will present at the Rodman & Renshaw Healthcare Conference held at the New York Palace Hotel, New York City from September 12-15, 2010.

Regenicin™ President Joe Connell will speak on Wednesday, September 15th at 11:15 am EDT to provide a status update on the company's Pipeline lead candidate PermaDerm™ as well as a general overview of Regenicin™, which went public in August.

About the Rodman Healthcare Conference

The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.

Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.

About Regenicin™

Regenicin™, Inc. is a clinical-stage company developing next generation tissue-engineered skin substitute to restore healthy human skin in severe burn victims. Through a strategic alliance with Lonza Group Ltd., the company has licensed breakthrough technology that utilizes a patient's own skin to generate living, tissue-engineered skin that has been used in clinical trials to treat burn victims.

With over 2,000 cases annually involving burns covering over 50% of a patient's body, according to the American Burn Association, the potential United States market size for Regenicin™'s product is in excess of $3 billion annually. The product could also be used for a wide variety of other applications, including the treatment of patients with chronic wounds or use in reconstructive plastic surgery.

As the key component to Regenicin™'s PermaDerm™ tissue-engineered skin, its biomedical polymer is an important commercial product that could be used for a variety of other applications separately, including as protection for organs and tendons, as a carrier for hormones or medicines, as a protective healing agent for wounds, or as a carrier for stem cells, making this company one worth watching for investors. (www.regenicin.com).


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 The U.S. Food and ... (empagliflozin) to reduce the risk of cardiovascular death in ... disease. "Cardiovascular disease is a leading ... mellitus," said Jean-Marc Guettier , M.D., C.M., director ... FDA,s Center for Drug Evaluation and Research. "Availability of ...
(Date:12/2/2016)... , December 2, 2016 Persistence ... pacemaker market in its upcoming report titled, "Global Market Study on ... Declining CAGR of -1.4% between 2016 and 2024". The global ... in 2015 and this is likely to decline to ... the global cardiac pacemaker market is anticipated to exhibit ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... More than half of American teens report losing their virginity before they ... child about sex related topics, less than 60 percent spoke about deeper themes like ... launch of its second edition of the “Sexual Wellness” campaign, aiming to address the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... Viejo, California (PRWEB) , ... December 02, 2016 , ... ... will allow FCPX editors to create versatile lower third titles with just a few ... , Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various styles ...
(Date:12/2/2016)... Pass, OR (PRWEB) , ... December 02, 2016 ... ... Wein, Medical Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s ... host of The Sharon Kleyne Hour Power of Water, Global Climate Change and ...
(Date:11/30/2016)... ... 2016 , ... "I hate when the mixture of saliva and toothpaste runs ... inventor from Bridgewater, N.J. "I thought that there had to be a way to ... the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle ...
Breaking Medicine News(10 mins):